- Home
- REVG vs GLPG Comparison
REVG vs GLPG Comparison
Compare REVG & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVG
- GLPG
- Stock Information
- Founded
- REVG 2008
- GLPG 1999
- Country
- REVG United States
- GLPG Belgium
- Employees
- REVG N/A
- GLPG N/A
- Industry
- REVG Auto Manufacturing
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- REVG Consumer Discretionary
- GLPG Health Care
- Exchange
- REVG Nasdaq
- GLPG Nasdaq
- Market Cap
- REVG 2.2B
- GLPG 1.9B
- IPO Year
- REVG 2017
- GLPG 2005
- Fundamental
- Price
- REVG $48.56
- GLPG $30.32
- Analyst Decision
- REVG Hold
- GLPG Sell
- Analyst Count
- REVG 4
- GLPG 4
- Target Price
- REVG $41.25
- GLPG $25.33
- AVG Volume (30 Days)
- REVG 679.0K
- GLPG 239.4K
- Earning Date
- REVG 09-03-2025
- GLPG 07-23-2025
- Dividend Yield
- REVG 0.49%
- GLPG N/A
- EPS Growth
- REVG N/A
- GLPG N/A
- EPS
- REVG 1.86
- GLPG N/A
- Revenue
- REVG $2,331,500,000.00
- GLPG $311,493,731.00
- Revenue This Year
- REVG $3.60
- GLPG $0.78
- Revenue Next Year
- REVG $6.89
- GLPG N/A
- P/E Ratio
- REVG $26.04
- GLPG N/A
- Revenue Growth
- REVG N/A
- GLPG 18.32
- 52 Week Low
- REVG $21.54
- GLPG $22.36
- 52 Week High
- REVG $50.34
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- REVG 65.57
- GLPG 67.62
- Support Level
- REVG $48.03
- GLPG $28.21
- Resistance Level
- REVG $50.34
- GLPG $30.64
- Average True Range (ATR)
- REVG 1.23
- GLPG 0.52
- MACD
- REVG -0.11
- GLPG 0.23
- Stochastic Oscillator
- REVG 72.02
- GLPG 91.29
About REVG REV Group Inc.
REV Group Inc is a United States-based designer, manufacturer, and distributor of specialty vehicles and related aftermarket parts and services. During the first fiscal quarter of 2024, the Company formed the Specialty Vehicles Segment by combining the Fire & Emergency and Commercial segment businesses. Additionally, the Recreation segment was renamed Recreational Vehicles. As a result, the Company is now organized into two reportable segments. The company operates in the United States, Canada, and the rest of the world. Maximum of revenue is gained from Specialty Vehicles Segment.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.